Managers / Q1 2023 · view latest →
TRV GP III, LLC
CIK 0001637299 · THIRD ROCK VENTURES, 201 BROOKLINE AVE, SUITE 1401, BOSTON, MA, 02215 · (617)585-2000
Summary
Trv GP III, LLC reported $83M in U.S.-listed holdings across 3 positions for Q1 2023.
The portfolio is heavily concentrated: PLRX alone accounts for 59.0% of reported value.
Compared with Q4 2022, the fund opened 0 new positions and exited 2.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 88.6% · $73M
- Other · 11.4% · $9M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2022 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| RVMDREVOLUTION MEDICINES, INC. | SOLD OUT | −1.60M | 0 | −$38M | $0 |
| FULCFULCRUM THERAPEUTICS, INC. | SOLD OUT | −1.96M | 0 | −$14M | $0 |
| VYGRVOYAGER THERAPEUTICS, INC. | TRIMMED | −2.24M | 3.19M | −$9M | $25M |
| PLRXPLIANT THERAPEUTICS, INC. | HELD | +0 | 1.84M | +$13M | $49M |
| DECIBEL THERAPEUTICS, INC. | HELD | +0 | 3.14M | +$3M | $9M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2023
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | PLRXPLIANT THERAPEUTICS, INC.history → | COM | 58.97% | $49M | 1.84M |
| 2 | VYGRVOYAGER THERAPEUTICS, INC.history → | COM | 29.60% | $25M | 3.19M |
| 3 | DECIBEL THERAPEUTICS, INC. | COM | 11.43% | $9M | 3.14M |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q4 2023 | $6M | 1 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $6M | 1 | Nov 13, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $18M | 2 | Aug 10, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $83M | 3 | May 12, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $128M | 5 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $229M | 6 | Nov 3, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $244M | 7 | Aug 12, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $369M | 7 | May 10, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $400M | 7 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $527M | 7 | Nov 5, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $573M | 7 | Aug 11, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $791M | 7 | May 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $1.2B | 7 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $1.2B | 7 | Nov 6, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $685M | 5 | Aug 7, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $368M | 5 | May 11, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $226M | 4 | Feb 5, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $176M | 4 | Nov 4, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $235M | 3 | Aug 6, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $204M | 3 | May 3, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $119M | 3 | Jan 28, 2019 | 13F-HR | changes · EDGAR ↗ |
Other Included Managers
This filing reports holdings on behalf of 1 additional manager.
- Robert I. Tepper028-18419
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.